Helus Pharma (NASDAQ:HELP) reported financial results and clinical progress for the third quarter of fiscal 2026 ended December 31, 2025, highlighting a solid cash position and advancing late-stage programs targeting major psychiatric indications.
Cash, cash equivalents, and short-term investments totaled $195.1 million as of December 31, 2025.
The quarter resulted in a net loss of $42.7 million, with cash-based operating expenses of $36.7 million.
Pipeline updates include ongoing advancement of oral blarcamesine (HLP004) in generalized anxiety disorder (GAD), with topline Phase 2 data expected in the first quarter of 2026, and continued enrollment in the Phase 3 program for HLP003 in major depressive disorder (MDD), with topline data anticipated in the fourth quarter of 2026.
Meanwhile, intellectual property protection for the lead programs extends through at least 2041.